Body fluid biomarkers in multiple sclerosis

The Lancet Neurology

Volumn 13, Issue 1, 2014, Pages 113-126

  Comabella, Manuel ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; AQUAPORIN 4 ANTIBODY; BETA INTERFERON; BIOLOGICAL MARKER; CYSTATIN C; GELATINASE B; IMMUNOGLOBULIN G ANTIBODY; MICRORNA; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; NEUTRALIZING ANTIBODY; OSTEOPONTIN; PROTEIN NOGO A;

BODY FLUID; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DEMYELINATING DISEASE; DISEASE ACTIVITY; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNITY; JC VIRUS; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROFILAMENT; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VALIDATION PROCESS; VARICELLA ZOSTER VIRUS;

ANIMALS; BIOLOGICAL MARKERS; BODY FLUIDS; HUMANS; MULTIPLE SCLEROSIS;

EID: 84892176685     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70233-3     Document Type: Review

References (170)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
2. Lublin FD, Reingold SC Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
3. Bielekova B, Kadom N, Fisher E, et al. 3. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005, 65:1071-1076.
4. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
5. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013, 73:95-103.
6. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009, 72:1322-1399.
7. Gunnarsson M, Malmeström C, Axelsson M, et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011, 69:83-89.
8. Miller DH, Chard DT, Ciccarelli O Clinically isolated syndromes. Lancet Neurol 2012, 11:157-169.
9. Granberg T, Martola J, Kristoffersen-Wiberg M, Aspelin P, Fredrikson S Radiologically isolated syndrome - incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review. Mult Scler 2013, 19:271-280.
10. Lassmann H, Brück W, Lucchinetti CF The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
11. Rifai N, Gillette MA, Carr SA Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
12. Ding W, Qiu P, Liu YH, Feng W Current omics technologies in biomarker discovery. Handbook of research on computational and systems biology: interdisciplinary applications 2011, 79-113. IGI Global, Hershey, PA. L.A. Liu (Ed.).
13. Ottervald J, Franzén B, Nilsson K, et al. Multiple sclerosis: identification and clinical evaluation of novel CSF biomarkers. J Proteomics 2010, 73:1117-1132.
14. Stoop MP, Singh V, Dekker LJ, et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5:e12442.
15. Teunissen CE, Koel-Simmelink MJ, Pham TV, et al. Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler 2011, 17:838-850.
16. Del Boccio P, Pieragostino D, Lugaresi A, et al. Cleavage of cystatin C is not associated with multiple sclerosis. Ann Neurol 2007, 62:201-204.
17. Guerau-de-Arellano M, Alder H, Ozer HG, Lovett-Racke A, Racke MK miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 2012, 248:32-39.
18. Waschbisch A, Sandbrink R, Hartung HP, et al. Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. Neurology 2011, 77:596-598.
19. Lindsey JW, Crawford MP, Hatfield LM Soluble Nogo-A in CSF is not a useful biomarker for multiple sclerosis. Neurology 2008, 71:35-37.
20. Kuhle J, Pohl C, Mehling M, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med 2007, 356:371-378.
21. Correale J, Fiol M Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 2011, 17:521-531.
22. Corvol JC, Pelletier D, Henry RG, et al. Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA 2008, 105:11839-11844.
23. Bartosik-Psujek H, Archelos JJ Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG. J Neurol 2004, 251:414-420.
24. Guimarães I, Cardoso MI, Sá MJ Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis. Mult Scler 2006, 12:354-356.
25. Silber E, Semra YK, Gregson NA, Sharief MK Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58:1372-1381.
26. Bartos A, Fialová L, Soukupová J, Kukal J, Malbohan I, Pitha J Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007, 116:100-107.
27. Bittner S, Bobak N, Herrmann AM, et al. Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann Neurol 2010, 68:58-69.
28. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008, 65:337-344.
29. Comabella M, Craig DW, Morcillo-Suárez C, et al. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009, 66:972-978.
30. Bushnell SE, Zhao Z, Stebbins CC, et al. Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology 2012, 79:531-537.
31. Sundström P, Juto P, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62:2277-2282.
32. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006, 63:839-844.
33. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011, 17:1185-1193.
34. Desplat-Jégo S, Feuillet L, Pelletier J, Bernard D, Chérif AA, Boucraut J Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry. J Clin Immunol 2005, 25:338-345.
35. Presslauer S, Milosavljevic D, Brücke T, Bayer P, Hübl W Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol 2008, 255:1508-1514.
36. Kaplan B, Aizenbud BM, Golderman S, Yaskariev R, Sela BA Free light chain monomers in the diagnosis of multiple sclerosis. J Neuroimmunol 2010, 229:263-271.
37. Villar LM, Sádaba MC, Roldán E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
38. Sola P, Mandrioli J, Simone AM, et al. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 2011, 17:303-311.
39. Magraner MJ, Bosca I, Simó-Castelló M, et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 2012, 54:5-12.
40. Durante L, Zaaraoui W, Rico A, et al. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler 2012, 18:587-591.
41. Ferraro D, Simone AM, Bedin R, et al. Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 2013, 257:76-81.
42. Massaro AR The role of NCAM in remyelination. Neurol Sci 2002, 22:429-435.
43. Strekalova H, Buhmann C, Kleene R, et al. Elevated levels of neural recognition molecule L1 in the cerebrospinal fluid of patients with Alzheimer disease and other dementia syndromes. Neurobiol Aging 2006, 27:1-9.
44. Gnanapavan S, Grant D, Illes-Toth E, Lakdawala N, Keir G, Giovannoni G Neural cell adhesion molecule-description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. J Neuroimmunol 2010, 225:118-122.
45. Giovannoni G, Silver NC, O'Riordan J, et al. Increased urinary nitric oxide metabolites in patients with multiple sclerosis correlates with early and relapsing disease. Mult Scler 1999, 5:335-341.
46. Brundin L, Morcos E, Olsson T, Wiklund NP, Andersson M Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 1999, 6:585-590.
47. Acar G, Idiman F, Idiman E, Kirkali G, Cakmakçi H, Ozakbaş S Nitric oxide as an activity marker in multiple sclerosis. J Neurol 2003, 250:588-592.
48. Rejdak K, Eikelenboom MJ, Petzold A, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology 2004, 63:1439-1445.
49. Waubant E, Goodkin D, Bostrom A, et al. IFN-beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003, 60:52-57.
50. Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003, 136:46-53.
51. Fainardi E, Castellazzi M, Bellini T, et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006, 12:294-301.
52. Benesová Y, Vasku A, Novotná H, et al. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Mult Scler 2009, 15:316-322.
53. Whitaker JN, Lisak RP, Bashir RM, et al. Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders. Ann Neurol 1980, 7:58-64.
54. Barkhof F, Frequin ST, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992, 42:63-67.
55. Lamers KJ, de Reus HP, Jongen PJ Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. Mult Scler 1998, 4:124-126.
56. Vogt MH, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004, 155:155-160.
57. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005, 158:231-239.
58. Börnsen L, Khademi M, Olsson T, Sørensen PS, Sellebjerg F Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011, 17:32-42.
59. Sellebjerg F, Börnsen L, Khademi M, et al. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009, 73:2003-2010.
60. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011, 17:335-343.
61. Ragheb S, Li Y, Simon K, et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011, 17:819-829.
62. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002, 125:1462-1473.
63. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63:1586-1590.
64. Axelsson M, Malmeström C, Nilsson S, Haghighi S, Rosengren L, Lycke J Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 2011, 258:882-888.
65. Sarchielli P, Greco L, Stipa A, Floridi A, Gallai V Brain-derived neurotrophic factor in patients with multiple sclerosis. J Neuroimmunol 2002, 132:180-188.
66. Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005, 62:176-182.
67. Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009, 460:130-132.
68. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
69. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. J Neurol Sci 1998, 155:44-49.
70. Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 2009, 4:e7638.
71. Comabella M, Fernández M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133:1082-1093.
72. Ingram G, Hakobyan S, Hirst CL, et al. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010, 133:1602-1611.
73. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009, 132:3353-3365.
74. Cenit MD, Blanco-Kelly F, de las Heras V, et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009, 15:913-917.
75. Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008, 83:219-227.
76. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
77. Wang H, Wang K, Zhong X, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 2012, 32:1007-1011.
78. Caminero A, Comabella M, Montalban X Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story. J Neuroimmunol 2011, 234:1-6.
79. Lovett-Racke AE, Yang Y, Racke MK Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochim Biophys Acta 2011, 1812:246-251.
80. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009, 41:824-828. The ANZgene Consortium.
81. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009, 18:767-778.
82. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009, 41:776-782.
83. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. International Multiple Sclerosis Genetics Consortium.
84. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011, 76:1206-1213.
85. Lim ET, Sellebjerg F, Jensen CV, et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Mult Scler 2005, 11:532-536.
86. Brettschneider J, Petzold A, Junker A, Tumani H Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006, 12:143-148.
87. Axelsson M, Malmeström C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2013, published online May 23. 10.1177/1352458513490544.
88. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832-2838.
89. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011, 10:436-445.
90. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012, 72:234-240.
91. Stewart N, Simpson S, van der Mei I, et al. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012, 79:254-260.
92. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009, 66:483-489.
93. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010, 9:381-390.
94. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
95. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
96. Sørensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011, 17:1074-1078.
97. Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011, 17:708-719.
98. Oliver B, Fernández O, Orpez T, et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler 2011, 17:368-371.
99. Lundkvist M, Engdahl E, Holmén C, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 2013, 19:757-764.
100. Sorensen P, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005, 12:817-827.
101. Goodin D, Frohman E, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007, 68:977-984.
102. Polman C, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9:740-750.
103. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005, 62:865-870.
104. Link H, Huang YM Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 2006, 180:17-28.
105. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
106. Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
107. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
108. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366:1870-1880.
109. Löebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012, 8:143-151.
110. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
111. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS, MRI Analysis GroupMRI Analysis Group.
112. Brambilla R, Ashbaugh JJ, Magliozzi R, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 2011, 134:2736-2754.
113. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008, 7:796-804.
114. Longbrake EE, Racke MK Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?. Expert Rev Neurother 2009, 9:319-321.
115. Beecham AH, Patsopoulos NA, Xifara DK Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. International Multiple Sclerosis Genetics Consortium (IMSGC). Nat Genet 2013, 45:1353-1360. for the International Multiple Sclerosis Genetics Consortium (IMSGC).
116. Gourraud PA, McElroy JP, Caillier SJ, et al. Aggregation of multiple sclerosis genetic risk variants in multiple and single case families. Ann Neurol 2011, 69:65-74.
117. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:5941-5946.
118. Bielekova B, Richert N, Herman ML, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011, 77:1877-1886.
119. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007, 69:1391-1403.
120. Wingerchuk DM, Weinshenker BG Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003, 60:848-853.
121. Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011, 70:742-750.
122. Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK Fingolimod treatment for multiple sclerosis patients. What do we do with varicella?. Ann Neurol 2011, 70:673-674.
123. Löbermann M, Boršo D, Hilgendorf I, Fritzsche C, Zettl UK, Reisinger EC Immunization in the adult immunocompromised host. Autoimmun Rev 2012, 11:212-218.
124. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999, 52:1239-1243.
125. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 2003, 60:634-639.
126. Hesse D, Sellebjerg F, Sorensen P Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009, 73:372-377.
127. Tintoré M, Rovira A, Río J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083.
128. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
129. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
130. Papeix C, Vidal J-S, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:255-259.
131. Warabi Y, Matsumoto Y, Hayashi H Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:257-261.
132. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010, 9:438-446.
133. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010, 68:295-303.
134. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
135. Uccelli A, Ginocchio F, Mancardi GL, Bassetti M Primary varicella zoster infection associated with fingolimod treatment. Neurology 2011, 76:1023-1024.
136. Monfort L, Muñoz D, Trenchs V, et al. Measles outbreak in Barcelona. Clinical and epidemiological characteristics. Enferm Infecc Microbiol Clin 2010, 28:82-86.
137. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30:886-890.
138. Gudewill S, Pollmächer T, Vedder H, Schreiber W, Fassbender K, Holsboer F Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992, 242:53-56.
139. Rababah M, Worthmann H, Deb M, et al. Anticoagulants affect matrix metalloproteinase 9 levels in blood samples of stroke patients and healthy controls. Clin Biochem 2012, 45:483-489.
140. Nikula T, Mykkänen J, Simell O, Lahesmaa R Genome-wide comparison of two RNA-stabilizing reagents for transcriptional profiling of peripheral blood. Transl Res 2013, 161:181-188.
141. Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
142. Berven FS, Kroksveen AC, Berle M, et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl 2007, 1:699-711.
143. West-Nielsen M, Hogdall EV, Marchiori E, Hogdall CK, Schou C, Heegaard NH Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem 2005, 77:5114-5123.
144. Scharbert G, Kalb M, Marschalek C, Kozek-Langenecker SA The effects of test temperature and storage temperature on platelet aggregation: a whole blood in vitro study. Anesth Analg 2006, 102:1280-1284.
145. Ledue TB, Rifai N Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003, 49:1258-1271.
146. Azuaje F Bioinformatics and biomarker discovery: "Omic" data analysis for personalized medicine 2010, John Wiley and Sons, Chichester.
147. Zhang Z, Chan DW The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev 2010, 19:2995-2999.
148. Comabella M, Martin R Genomics in multiple sclerosis-current state and future directions. J Neuroimmunol 2007, 187:1-8.
149. Teunissen C, Menge T, Altintas A, et al. Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler 2013, published online May 21. 10.1177/1352458513488232.
150. Chan A, Pirmohamed M, Comabella M Pharmacogenomics in neurology: current state and future steps. Ann Neurol 2011, 70:684-697.
151. Sawcer S The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008, 131:3118-3131.
152. Plebani M Errors in clinical laboratories or errors in laboratory medicine?. Clin Chem Lab Med 2006, 44:750-759.
153. Ioannidis JP Why most published research findings are false. PLoS Med 2005, 2:e124.
154. Broadhurst DI, Kell DB Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2007, 2:171-196.
155. Allison DB, Cui X, Page GP, Sabripour M Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 2006, 7:55-65.
156. Ram M, Sherer Y, Shoenfeld Y Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006, 26:299-307.
157. Lund SA, Giachelli CM, Scatena M The role of osteopontin in inflammatory processes. J Cell Commun Signal 2009, 3:311-322.
158. Whitaker JN, Williams PH, Layton BA, et al. Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis. Ann Neurol 1994, 35:577-585.
159. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
160. Cohen JA, Reingold SC, Polman CH, Wolinsky JS Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012, 11:467-476. for the International Advisory Committee on Clinical Trials in Multiple Sclerosis.
161. Ziegler A, Koch A, Krockenberger K, Großhennig A Personalized medicine using DNA biomarkers: a review. Hum Genet 2012, 131:1627-1638.
162. Dobson R, Topping J, Davis A, Thompson E, Giovannoni G Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand 2013, published online March 7. 10.1111/ane.12119.
163. Devos D, Forzy G, de Seze J, et al. Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. J Neurol 2001, 248:672-675.
164. Calais G, Forzy G, Crinquette C, et al. Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler 2010, 16:87-92.
165. Houser B Bio-Rad's Bio-Plex® suspension array system, xMAP technology overview. Arch Physiol Biochem 2012, 118:192-196.
166. Dybkaer R Vocabulary for use in measurement procedures and description of reference materials in laboratory medicine. Eur J Clin Chem Clin Biochem 1997, 35:141-173.
167. Bossuyt X Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8:543-548.
168. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 2011, 11:171-182.
169. Wolf CR, Smith G, Smith RL Science, medicine, and the future: pharmacogenetics. BMJ 2000, 320:987-990.
170. Río J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006, 59:344-352.